Seattle Genetics (SGEN) Delivers at ASH - Needham & Company

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015

-Updated Phase 2 Data Evaluating ADCETRIS in Combination with RCHOP Chemotherapy in Frontline CD30-Expressing High Risk DLBCL Demonstrate an 84 Percent Objective Response Rate with a 76 Percent Complete Remission Rate-

-Updated Phase 1 Data Evaluating ADCETRIS in Combination with CHP Chemotherapy in Frontline Mature T-Cell Lymphoma Demonstrate a Three-Year Overall Survival Rate of 80 Percent, with Estimated Median Progression-Free Survival Not Yet Reached-

ORLANDO, Fla.--(BUSINESS WIRE)--... More

Seattle Genetics Demonstrates Commitment to Improve Hodgkin Lymphoma (HL) Treatment Paradigm Through Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations at ASH 2015

-Final Pivotal Trial Results in Relapsed/Refractory HL Demonstrate Durable Remissions Lasting More than Five Years After ADCETRIS Monotherapy-

-Data From Multiple Presentations Support Goal to Establish ADCETRIS as the Foundation of Care for HL-

-ADCETRIS Being Evaluated Broadly in more than 45 HL Clinical Trials-

ORLANDO, Fla.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq:... More

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data Presentations in Patients with Acute Myeloid Leukemia at ASH 2015

-33A Combination Therapy and Monotherapy Demonstrate Encouraging Anti-leukemic Activity in AML; Data Highlighted in Oral Presentations-

-Planning 33A Phase 3 Trial in Older AML Patients-

ORLANDO, Fla.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted several data presentations at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in... More

Seattle Genetics Highlights Data from Denintuzumab Mafodotin (SGN-CD19A) Antibody-Drug Conjugate Program at ASH 2015

-Updated Data from Phase 1 Clinical Trials Support Further Clinical Evaluation of SGN-CD19A in Randomized Phase 2 Trials: Testing Novel Regimens for Frontline and Relapsed DLBCL-

-First Preclinical Data Presented for SGN-CD19B, a Novel Antibody-Drug Conjugate with PBD Dimer Payload; Phase 1 Clinical Trial in B-cell Malignancies to Begin in 2016-

ORLANDO, Fla.--(BUSINESS WIRE)-- Seattle Genetics, Inc.... More